LBPS 4D pharma plc ADRs

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.? 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism. This is an ADR of a company whose stock trades outside of the U.S. as the symbol LN:DDDD.

$6.79  -0.46 (-6.35%)
As of 10/26/2021 15:49:08 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  03/22/2021
Outstanding shares:  22,537,621
Average volume:  18,896
Market cap:   $167,229,148
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   -23.51
PB ratio:   4.07
PS ratio:   304.05
Return on equity:   -17.30%
Net income %:   -4,991.27%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy